Pre-Conference Workshop Day | Wednesday October 9, 2024

08:30am Registration

Workshop A | 9.00 – 10.30

Establishing Your Biopharma ESG Strategy & Adhering to US Regulation for Biotech Organizations

Synopsis

Designed for life sciences organizations at the early stage of their ESG journey, join this interactive workshop session to uncover how to get continued buy-in to your ESG and sustainability strategy and execute this with limited budget and resources. This session is designed for the biopharma organizations early in their ESG journey

seeking to connect with peers at similar stages of progress to brainstorm key content, uncover best practices, and benchmark among peers. Walk away with a roadmap to ensure regulatory compliance (in the US only) and secure the future of your ESG function in 2024 and beyond.

Content this session will cover:

  • What environmental and social issues to prioritize at the start of your journey and a year on including, how and when to establish a baseline, the context of goal setting, and how to get there (including alignment with TCFD)
  • An overview of the ESG regulatory environment in USA (i.e. updates to the SEC and California Environmental Bills) and understanding the current evolutions and what you need to comply to
  • How to effectively collect environmental data for compliance with SEC, California and other US-based regulation: what tools and technology to use, now but also in the future, and ensuring the integrity of data collection
  • How do you operationally set up your teams (audit, finance, etc) to support ESG and sustainability reporting for compliance

10:30am Networking Break

Workshop B | 11.00 – 12.30

Tackling CSRD, Double Materiality & Other Global Regulations for Biotech Organizations

  • Sandra Yi-Fuller Head of Corporate Responsibility & Reporting, Biogen
  • Arun Skaria Senior Director, Corporate Responsibility and ESG, Alnylam Pharmaceuticals

Synopsis

Uncover how growing biotech organizations with smaller teams than large pharma are complying to evolving new ESG policy and regulations. This includes a roadmap on how to comply to CSRD regulations across KPIs (and develop a human right policy) to ensure global regulatory compliance in 2024. Walk away with a roadmap to ensure regulatory compliance (globally) and secure the future of your ESG function in 2024 and beyond.

Content this session will cover:

  • An overview of the global ESG regulatory environment (CSRD, SEC, California Climate Bills) and understanding the current evolutions
  • How to comply to CSRD and complete a double materiality assessment in biotech organizations: understanding timelines, using the best technology, ensuring integrity of data collection, putting this into an auditable report
  • Developing a Human Rights policy in accordance to CSRD and UK regulation
  • How to effectively collect environmental data for compliance to CSRD: what tools and technology to use, now but also in the future and ensuring integrity of data collection
  • How do you operationally set up your teams (audit, finance etc) to support ESG and sustainability reporting for compliance

12:30pm Lunch

Workshop C | 1.30 – 3.00

Evolving Your Biopharma ESG Reporting Strategy & Preparing for Regulatory ESG Disclosures

  • Kyle Cahill Global Head, Environmental Sustainability Disclosure and Engagement, Takeda Pharmaceutical Company
  • Hollie Grant Associate Director, Global Sustainability, Takeda Pharmaceutical Company

Synopsis

Deep dive into how life sciences organizations are preparing to enhance their ESG and sustainability reporting in a rapidly evolving regulatory landscape. Learn how your peers approach their double materiality assessments, connect the dots between different disclosure frameworks, and evolve ESG operating models to enhance crossfunctional collaboration and ensure regulatory compliance.

Content this session will cover:

  • Overview of key ESG regulations for large biopharma companies in the US (CSRD, SEC climate disclosure rule, California Climate Bills, CS3D) and their links to other disclosure frameworks
  • Preparing for CSRD reporting: Conducting a double materiality assessment (DMA) and identifying relevant disclosures, ensuring data integrity and the role of technology, developing an auditable report
  • Integrating the DMA with existing enterprise risk management processes
  • Considering CS3D in your preparations for CSRD
  • Enhancing your ESG operating model and cross-functional collaboration: Engaging key stakeholders (e.g. subject matter experts, legal, finance, audit, communications) to operationalize regulatory ESG disclosure readiness

3:00pm Networking Break

Workshop D | 3.30 – 5.00

Moving Beyond Compliance & Refining an Overarching Sustainable Business Strategy

  • Byron Austin Global Head, ESG, Sustainability, and Corporate Responsibility, Organon

Synopsis

Join this interactive workshop style roundtable discussion session and uncover how to refine your overarching ESG strategy to secure your future as a truly sustainable business. This session is designed with the strategic ESG leader in mind. It will be tailored to ensure leaders in small biotechs with limited resources, to large pharma alike can connect with their peers at similar stages of their ESG journey to brainstorm key content.

Content this session will cover:

  • Moving beyond compliance: what does new regulation mean for overall strategy?
  • How can we leverage regulation as a characteristic for transforming the business?
  • What is the fate of your voluntary strategy and how can we ensure ESG and sustainability does not become a compliance function?

5:00pm End of Workshop Day